

Ensayos Clínicos de **TIROIDES** Abiertos a Reclutamiento (Actualizado_abril_2021)

FUENTE de la INFORMACIÓN OBTENIDA: Clinical Trials.gov; EU Clinical Trials Register; REEC (AEMPS)

| Eudract_Number | NCT | CODIGO_ESTUDIO | TITULO DEL ESTUDIO | FASE_ESTUDIO | INDICACION | ESTADO | MEDICACION | CENTROS_PARTICIPANTES | PROMOTOR | ESPECIALIDAD | COMENTS |
|----------------|---------|----------------------|--|---------------------------|--|------------|---|--|--|------------------|---------|
| 2018-002512-27 | 3780517 | BOS172738-01 | A Phase 1 Study of BOS172738 in Patients With Advanced Solid Tumors With RET Gene Alterations Including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC) | Phase I | Advanced Nonhaematologic Malignancies | RECLUTANDO | BOS172738 | H.U.Victoria (Malaga) IDC Basiltona (BCN) H.U. Quiron Donesur (BCN) START_Sanchinarro (Madrid) START_F.J. Diaz (Madrid) | Boston Pharmaceuticals | Oncologia_Medica | N= 114 |
| 2018-004338-15 | 4234113 | SC103 | A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors | Phase I | HN5CC & Thyroid. A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors | RECLUTANDO | SO-C101 Pembrolizumab | H.U. Vall d'Hebron (BCN) | SOTID | Oncologia_medica | N= 96 |
| 2017-001792-24 | 3170960 | XL184-021 | A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Phase Ib | Expansion Cohort 1B: DTC subjects (follicular, papillary, and poorly differentiated histologies) who are radioactive iodine (RAI) refractory or deemed ineligible for treatment with RAI. | RECLUTANDO | Atezolizumab & Cabozantinib | H.U. Vall d'Hebron (BCN) C.M. Teknon (BCN) H.U. Clinic (BCN) H. Abr (BCN) C.H.U. Santiago H.U. Son Espases (B) H.U. 12 Octubre (Madrid) | Exelixis | Oncologia_medica | N= 1732 |
| 2016-004390-41 | 3037385 | BLU-667-1101 (ARROW) | A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors | Phase I/II | RET-altered NSCLC Medullary Thyroid Cancer RET-altered Papillary Thyroid Cancer RET-altered Colon Cancer RET-altered Solid Tumors | RECLUTANDO | BLU-667 | H.U. Vall d'Hebron (BCN) H.U. Clinic (BCN) IDC-Hospital (BCN) H.U. Ramon y Cajal (Madrid) H.U. 12 Octubre (Madrid) | Blueprint Medicines Corporation | Oncologia_Medica | N= 360 |
| 2017-000800-59 | 3157128 | LOXO-RET-17001 | A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) | Phase I / II | This is a Phase 1/2, open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to patients with advanced solid tumors, including RET-fusion-positive solid tumors, medullary thyroid cancer (MTC), and other tumors with RET activation. | RECLUTANDO | LOXO-292 | H.U. Vall d'Hebron (BCN) START_F.J. Diaz (Madrid) START_Sanchinarro (Madrid) | Loxo Oncology, Inc. | Oncologia_Medica | N= 970 |
| 2016-002243-42 | 2988817 | GCT1021-01 | First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax [®] -Axl-ADC) in Patients With Solid Tumors | Phase I / II | The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-Axl-ADC in a mixed population of patients with specified solid tumors. Thyroid Cancer | RECLUTANDO | Biological: Enapotamab vedotin (HuMax-Axl-ADC) | H.C. Lozano Blesa (Zaragoza) H.U. Puerta Hierro (Madrid) H.U. 12 Octubre (Madrid) IDC Girona IDC-Hospital (BCN) H.U. Vall d'Hebron (BCN) | Genmab | Oncologia_medica | N= 374 |
| 2015-002267-41 | 2628067 | 3475-158 | A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) | Phase II | Thyroid Carcinoma Salivary Gland Carcinoma (sarcomas and mesenchymal tumors are excluded) | RECLUTANDO | Pembrolizumab | H.U. Vall d'Hebron (BCN) H.U. Ramon y Cajal (Madrid) H.U. 12 Octubre (Madrid) | Merck Sharp & Dohme Corp | Oncologia_Medica | N= 1350 |
| 2015-003385-84 | 2568267 | RXDX-101-02 | An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | Phase II | Head and Neck Neoplasms, Papillary Thyroid Cancer, Salivary Gland Cancers, Adult Solid Tumor | RECLUTANDO | Entrectinib | H.U. Vall d'Hebron (BCN) H.U. Ramon y Cajal (Madrid) H.U. Clinica San Carlos (Madrid) H.U. 12 Octubre (Madrid) START-ODCC (Madrid) H.U.V. Victoria (Malaga) H.U.V. Rocio (Sevilla) | Hoffmann-La Roche / Igmya, Inc | Oncologia_Medica | N= 300 |
| 2018-001066-42 | 3753919 | GETNE-T1812 | Estudio de fase II de durvalumab (ME04750) más tremelimumab para el tratamiento de pacientes con carcinoma tiroideo avanzado, resistente al tratamiento y progresivo (ensayo DUTHY) | Phase II | Carcinoma de tiroides diferenciado, avanzado, refractario al yodo radiactivo, incluyendo carcinoma tiroideo papilar, folicular, de células de hirtle y poco diferenciado (CDT). Carcinoma medular de tiroides (CMT) avanzado. Cáncer anaplásico de tiroides (CAT) avanzado. | RECLUTANDO | Durvalumab (L.V) | C.I.I. Navarro H. Vall d'Hebron IDC Hospital (BCN) H.U. Morales Meseguer (Murcia) H.U. Ramon y Cajal (Madrid) H.U. 12 Octubre (Madrid) H.U. La Paz (Madrid) H.U. Victoria (Malaga). H.U. Clinic (BCN) M.D. Anderson (Madrid) H.U. San Chinarro (Madrid) H.C.U. San Carlos (Madrid) C.I. Castellón I.V.O. Valencia H.U. Alvaro Cunqueiro (Vigo) | Spanish Group of Neuroendocrine Tumors (GETNE) | Oncologia_Medica | N= 46 |
| 2016-003616-13 | 3091116 | TPX-0005-01 | A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) | Phase II in Spain | A Study of Reprectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) | RECLUTANDO | Oral Reprectinib (TPX-0005) | C.U. Navarra H.U. Donesur (BCN) H.U. Vall d'Hebron (BCN) M.D. Anderson (Madrid) San Carlos (Madrid) Start_Sanchinarro (Madrid) H.U. 12 Octubre (Madrid) I.V.O. Valencia | Turning Point Therapeutics, Inc. | Oncologia_medica | N= 450 |
| 2018-001771-21 | 3690388 | XL184-311 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy | Phase III | The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior VEGFR-Targeted therapy. | RECLUTANDO | Cabozantinib | H.U. 12 Octubre (Madrid) H.C.U. San Carlos (Madrid) H.U. Ramon y Cajal (Madrid) H.U. La Paz (Madrid) H.U. San Chinarro (Madrid) M.D. Anderson (Madrid) C.U. Navarra H.U. Vall d'Hebron (Madrid) H.U.V. Victoria (Malaga) H.U. Clinic (BCN) | Exelixis | Oncologia_medica | N= 300 |
| 2019-001978-28 | 4211337 | J2G-MC-I2IB | A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) | Phase III | The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. | RECLUTANDO | Drug: Selpercatinib Drug: Cabozantinib Drug: Vandetanib | H.V. Victoria (Malaga) H.U. Clinic (Madrid) H.U. 12 Octubre (Madrid) H.U. La Paz (Madrid) H.U. Ramon y Cajal (Madrid) H.U. G. Marañon (Madrid) IDC_Girona IDC_Hospital H.U. Vall d'Hebron (BCN) C.U. Navarra H.U. Miguel Servet | Lilly | Oncologia_medica | N= 400 |
| UK | 3765333 | REGTNE-Tiroides | Descriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and Anaplastic. | Descriptive Observational | NA | RECLUTANDO | NA | H.U. Vall d'Hebron | GETNE | Oncologia_Medica | N= 20 |